Asiakem Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 6 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.00 M
- Revenue Growth 124.53%
- Profit Growth 865.23%
- Ebitda 767.32%
- Net Worth 23.68%
- Total Assets 19.65%
About Asiakem Pharmaceuticals
Asiakem Pharmaceuticals Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 March 2018 (Six years and 11 months 19 days old ). Its registered office is in Khorda, Odisha, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹3.00 M.
Sarita Padhy and Litu Padhy serve as directors at the Company.
Company Details
- Location
Khorda, Odisha, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U93090OR2018PTC028466
- Company No.
028466
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Mar 2018
- Date of AGM
22 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Cuttack
Industry
Who are the key members and board of directors at Asiakem Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sarita Padhy  | Director | 09-Mar-2018 | Current |
| Litu Padhy | Director | 09-Mar-2018 | Current |
Financial Performance of Asiakem Pharmaceuticals.
Asiakem Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 124.53% increase. The company also saw a substantial improvement in profitability, with a 865.23% increase in profit. The company's net worth Soared by an impressive increase of 23.68%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Asiakem Pharmaceuticals?
In 2021, Asiakem Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹3.00 M
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 0.30 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Jul 2023 | Canara Bank | ₹3.00 M | Open |
How Many Employees Work at Asiakem Pharmaceuticals?
Unlock and access historical data on people associated with Asiakem Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Asiakem Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Asiakem Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.